Silexion Therapeutics Corp
For the period ended Jun 30, 2024. Filed Aug 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 29, 2024
SLXN$0.11-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
| Six months ended June 30 | Three months ended June 30 | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| U.S. dollars in thousands · U.S. dollars in thousands | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss | $(2,912) | $(2,619) | $(1,489) | $(1,876) |
| Adjustments required to reconcile loss to net cash used in operating activities: | ||||
| Depreciation | 15 | 29 | 7 | 14 |
| Share-based compensation expenses | 64 | 64 | 32 | 32 |
| Non-cash financial expenses | 219 | 257 | 83 | 278 |
| Changes in operating assets and liabilities: | ||||
| Increase (decrease) in prepaid expenses | (192) | (2) | (63) | 5 |
| decrease in other receivables | (42) | (9) | 2 | (20) |
| Increase (decrease) in trade payable | (38) | (57) | 37 | (52) |
| Net change in operating lease | 4 | (5) | 2 | (2) |
| Increase (decrease) in employee related obligations | 44 | (62) | (3) | (20) |
| Increase (decrease) in accrued expenses | 21 | (183) | 327 | (35) |
| Net cash used in operating activities | (2,817) | (2,587) | (1,065) | (1,676) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Proceeds from short-term deposit | - | 507 | - | - |
| Purchase of property and equipment | (6) | (2) | - | (2) |
| Net cash provided by (used in (investing activities | (6) | 505 | - | (2) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from issuance of preferred shares and warrants, net of issuance costs | - | 522 | - | 522 |
| Exercise of options | * | - | - | - |
| Net cash provided by financing activities | * | 522 | - | 522 |
| DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (2,823) | (1,560) | (1,065) | (1,156) |
| EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (75) | (258) | (19) | (277) |
| BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD | 4,645 | 8,309 | 2,831 | 7,924 |
| BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD | $1,747 | $6,491 | $1,747 | $6,491 |
| * | Represents an amount less than $1 |
|---|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Six months ended June 30 | Three months ended June 30 | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| U.S. dollars in thousands · U.S. dollars in thousands | ||||
| Appendix A – | ||||
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS: | ||||
| Cash and cash equivalents | 1,697 | 6,442 | 1,697 | 6,442 |
| Restricted cash | 50 | 49 | 50 | 49 |
| TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS | $1,747 | $6,491 | $1,747 | $6,491 |
| Appendix B - SUPPLEMENTARY INFORMATION: | ||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||
| Interest received | $25 | $78 | $6 | $39 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.